BRIVA-LIFE–A multicenter retrospective study of the long-term use of brivaracetam in clinical practice
Villanueva, V. ; López-González, F.J. ; Mauri, J.A. (Universidad de Zaragoza) ; Rodriguez-Uranga, J. ; Olivé-Gadea, M. ; Montoya, J. ; Ruiz-Giménez, J. ; Zurita, J. ; Abril, J. ; Toledo, M. ; Garcés, M. ; Gómez-Ibáñez, A. ; Hampel, K. ; Rodriguez-Osorio, X. ; Poza, J.J. ; Campos, D. ; Ojeda, J. ; Tortosa, D. ; Castro-Vilanova, M.D. ; Saiz-Diaz, R. ; González de la Aleja, J. ; Castillo, A. ; de Toledo, M. ; Gago-Veiga, A.B. ; Piera, A. ; Crisostomo, J. ; for, the, BRIVA-LIFE, study, group
Resumen: Objectives: Evaluate long-term effectiveness and tolerability of brivaracetam in clinical practice in patients with focal epilepsy.
Materials and Methods: This was a multicenter retrospective study. Patients aged =16 years were started on brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical records at 3, 6 and 12 months after treatment initiation for evaluation of safety- and seizure-related outcomes.
Results: A total of 575 patients were included in analyses; most had been treated with =4 lifetime antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12 months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were =50% responders and 17.5% were seizure-free. Seizure-freedom was achieved by 37.5% of patients aged =65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) was 39.8% and 14.3%, respectively, and discontinuation due to these was 8.9% and 3.7%, respectively. Somnolence, irritability, and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10-15). Among those who switched because of PAEs (n = 53), 9 (17%) reported PAEs on brivaracetam, and 3 (5.7%) discontinued because of PAEs. Tolerability was not highly affected among patients with learning disability or psychiatric comorbidity.
Conclusions: In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
Idioma: Inglés
DOI: 10.1111/ane.13059
Año: 2018
Publicado en: ACTA NEUROLOGICA SCANDINAVICA 139, 4 (2018), 360 - 368
ISSN: 0001-6314
Factor impacto JCR: 2.852 (2018)
Categ. JCR: CLINICAL NEUROLOGY rank: 86 / 199 = 0.432 (2018) - Q2 - T2
Factor impacto SCIMAGO: 1.225 - Medicine (miscellaneous) (Q1) - Neurology (clinical) (Q1) - Neurology (Q1)
Tipo y forma: Artículo (PrePrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2020-06-09-13:23:09)
Visitas y descargas
Materials and Methods: This was a multicenter retrospective study. Patients aged =16 years were started on brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical records at 3, 6 and 12 months after treatment initiation for evaluation of safety- and seizure-related outcomes.
Results: A total of 575 patients were included in analyses; most had been treated with =4 lifetime antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12 months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were =50% responders and 17.5% were seizure-free. Seizure-freedom was achieved by 37.5% of patients aged =65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) was 39.8% and 14.3%, respectively, and discontinuation due to these was 8.9% and 3.7%, respectively. Somnolence, irritability, and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10-15). Among those who switched because of PAEs (n = 53), 9 (17%) reported PAEs on brivaracetam, and 3 (5.7%) discontinued because of PAEs. Tolerability was not highly affected among patients with learning disability or psychiatric comorbidity.
Conclusions: In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
Idioma: Inglés
DOI: 10.1111/ane.13059
Año: 2018
Publicado en: ACTA NEUROLOGICA SCANDINAVICA 139, 4 (2018), 360 - 368
ISSN: 0001-6314
Factor impacto JCR: 2.852 (2018)
Categ. JCR: CLINICAL NEUROLOGY rank: 86 / 199 = 0.432 (2018) - Q2 - T2
Factor impacto SCIMAGO: 1.225 - Medicine (miscellaneous) (Q1) - Neurology (clinical) (Q1) - Neurology (Q1)
Tipo y forma: Artículo (PrePrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2020-06-09-13:23:09)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2019-12-12, última modificación el 2020-06-09